Protocol T: Little Difference In Eylea, Lucentis Efficacy At Two Years

The 660-patient Protocol T clinical trial, which was designed to compare the efficacy and safety of three vascular endothelial growth factor (VEGF) inhibitors used to treat diabetic macular edema (DME), show that the efficacy gap between Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) and Genentech's Lucentis (ranibizumab) at one year narrowed with no major difference in the second year.

In results published a year ago for the primary endpoint of gain in visual acuity at one year, Eylea bested...